Andrew Kolodny: Prevent Harm
Prefer to Read? Here Are the Key Points from This Episode
Dr. Andrew Kolodny, medical director of the Opioid Policy Research Collaborative at Brandeis University, frames the opioid crisis as an epidemic of opioid addiction rooted in aggressive prescribing, pharmaceutical influence, regulatory failure, and inadequate access to treatment. The episode moves beyond blame toward a systems-level examination of what led to this public health crisis, and raises difficult questions about pharmaceutical accountability, sealed litigation records, settlement funds, cannabis legalization, kratom, chronic pain, and the need for more nuanced policy than simple prohibition or legalization. His solution centers on preventing new cases of opioid addiction while making effective treatment easier to access than illicit opioids. He talked about all of this and more in his conversation with Zoe Weil:
- Opioid Addiction Is the Underlying Driver. The episode reframes overdose deaths by distinguishing the drug involved from the condition driving most deaths. Fentanyl is now commonly present in toxicology reports, but Kolodny emphasizes that most people dying from fentanyl overdoses are suffering from opioid addiction. This distinction matters because a fentanyl-only frame can narrow the solution to drug supply, while the deeper public health task remains prevention and treatment. The shift in language moves the audience from crisis reaction toward root-cause understanding.
- System Failures Went Beyond One Company. The crisis is presented as the result of multiple institutional failures, not simply the misconduct of Purdue Pharma or the Sackler family. Kolodny points to regulatory breakdowns, pharmaceutical influence over medical education, and failures in systems designed to protect medical practice from industry pressure. This widens accountability without turning the episode into a blame exercise. The deeper concern is that without a full reckoning, similar harm could happen again through other prescription drugs.
- Treatment Must Be Easier Than Fentanyl. A central solution is making effective treatment easier, cheaper, and more accessible than the illicit opioid supply. Kolodny specifically identifies buprenorphine access as a short-term life-saving priority, especially when fentanyl is inexpensive and easy to obtain. His point is practical: people facing withdrawal will often choose the fastest available relief. A humane treatment system must therefore reduce friction, cost, and delay so recovery becomes the easier path.
- Settlement Money Needs Public Health Discipline. The opioid settlements create an opportunity, but Kolodny is careful not to overstate their impact. He notes that many counties are still struggling to determine how to use the funds, and it is too soon to know whether the money will be used effectively. The episode raises a vital accountability question: whether settlement dollars will repair harm or disappear into unrelated budget needs. This makes the litigation story less about punishment and more about whether resources reach the people and communities most affected.
- Prevention Requires Changing Prescribing Defaults. Kolodny’s prevention strategy includes a stronger default against routine opioid exposure. He proposes changing DEA registration policy so clinicians who want to prescribe more than three days of opioids would need additional certification, while preserving appropriate access for specialties such as cancer and palliative care. The point is not to deny pain relief, but to reduce unnecessary exposure and prevent leftover opioids from accumulating in homes. This gives the episode a concrete policy lever rather than a vague call for awareness.
View all recent Solutionary Voices episodes.